Author name: Ananta Kar

India’s healthcare boom has triggered an environmental emergency that most citizens never see. Every day, over 700 tonnes of potentially lethal waste emerge from hospitals nationwide. Syringes, blood-soaked dressings, pharmaceutical residues, and pathological materials pile up relentlessly. Mishandled, they become biological time bombs threatening communities and ecosystems alike. Yet within this crisis lies a burgeoning

Americans with diabetes face a brutal choice: pay exorbitant insulin prices or ration life-saving medication and risk severe health complications. This isn’t hyperbole—patients regularly skip doses, stretch supplies dangerously thin, or simply go without because insulin costs have spiraled beyond affordability for millions. Biocon Biologics, a global biosimilars leader, has extended its partnership with US-based

Most cancer treatments attack tumours directly with chemicals or radiation—blunt instruments causing collateral damage throughout the body. Theriva Biologics takes a fundamentally different approach: engineering viruses that selectively invade cancer cells, replicate inside them, and trigger immune responses while breaking down the protective barriers tumours build around themselves. This innovative strategy targets some of medicine’s